Welcome to our dedicated page for NEOGENOMICS SEC filings (Ticker: NEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NeoGenomics, Inc. filings document the regulatory record of an oncology diagnostics company whose common stock trades on Nasdaq under the symbol NEO. Form 8-K reports furnish quarterly and annual operating results, preliminary financial information, press release exhibits, and Regulation FD disclosures tied to the company’s clinical testing and diagnostic services business.
The company’s proxy materials cover board structure, director matters, executive compensation, equity awards, pay-versus-performance disclosures and annual meeting governance. Other material-event filings describe officer transitions, board appointments and resignations, and registered security information, including common stock par value and exchange listing details.
NeoGenomics, Inc. (NEO) announced that it furnished a press release reporting results for its third fiscal quarter of 2025. The press release, dated October 28, 2025, is included as Exhibit 99.1.
The company states this information is furnished and is not deemed “filed” under Section 18 of the Exchange Act, and it is incorporated by reference only if specifically referenced in other filings.
NeoGenomics (NEO) executive Alicia C. Olivo (EVP, GC & Business Development) reported an open-market sale of common stock. On 10/16/2025, she sold 4,918 shares at $10.00 per share under a Rule 10b5-1 trading plan. Following this transaction, she beneficially owns 43,022 common shares directly.
Her equity awards include multiple grants shown in the filing, such as stock options with exercise prices ranging from $9.45 to $48.99, and time- and performance-based stock units, including 107,450 options with a $13.05 exercise price and 63,238 restricted stock units. The filing notes standard vesting schedules and that once vested, shares of common stock are not subject to expiration.
Alicia C. Olivo, EVP, General Counsel & Business Development of NeoGenomics, reported a Form 4 reflecting a tax-related surrender and extensive outstanding equity awards. On 09/01/2025 she surrendered 1,666 shares to NeoGenomics to satisfy tax withholding upon the vesting of restricted stock, leaving 47,940 shares of common stock beneficially owned. The filing lists multiple stock options, restricted stock units (RSUs) and performance stock units (PSUs) across grants from 2019 through 2025, including large awards on 02/21/2025 of 107,450 options and 63,238 RSUs. Several PSUs have maximum payout caps (e.g., 19,508 target with 29,262 max; 25,330 target with 37,996 max) tied to share-price and revenue goals. Many options vest ratably over 3–4 years and, once vested, shares do not expire.
Neogenomics, Inc. Schedule 13G discloses that First Light Asset Management, LLC beneficially holds 9,544,749 shares of Neogenomics common stock (about 7.39% of the class). Mathew P. Arens is reported as beneficial owner of 9,784,749 shares (about 7.57%), which reflects his control of the manager plus 100,000 shares held directly and additional shares held jointly. The filing is submitted under Rule 13d-1(b), indicating these holdings are reported as passive and not intended to change or influence control of the issuer. The filing includes a joint filing agreement and identifies the reporting persons' business address.
Three related reporting persons — Greenhouse Funds LLLP, Greenhouse GP LLC and Joseph Milano — each report beneficial ownership of 7,431,147 shares of NeoGenomics common stock, representing 5.8% of the class. The filing shows no sole voting or dispositive power and reports shared voting power of 6,658,116 and shared dispositive power of 7,431,147, indicating joint control over voting and disposition rather than individual control.
The statement explains these securities are directly owned by advisory clients of Greenhouse Funds LLLP, that the holdings were acquired and are held in the ordinary course of business and were not acquired to influence control of the issuer, and includes a disclaimer limiting claimed beneficial ownership to pecuniary interest.
NeoGenomics disclosed that director Elizabeth Floegel resigned from the Company’s Board, effective immediately. The filing expressly states her resignation did not result from any disagreement with the Company on its operations, policies or practices. The notice is a straightforward governance update recorded under Item 5.02 and does not include any additional information about reasons beyond the statement or any immediate replacement for the Board seat.
This disclosure informs investors of a change in board composition while explicitly denying any dispute with management; the filing contains no financial data, operational changes or other material transactions.
Key takeaways from CEO Anthony P. Zook’s Form 4 filing (NEO, filed 6 Aug 2025):
- On 06 Aug 2025 Zook executed an open-market purchase (code P) of 17,900 common shares at $5.584, raising his direct stake to 38,066 shares; he also beneficially owns 18,900 shares via a trust.
- No shares were sold or otherwise disposed.
- Derivative holdings disclosed: 8,353 options @ $14.82 (exercisable 10 Aug 2024–10 Aug 2033), 8,672 options @ $13.71 (1 Jun 2025–1 Jun 2034) and a premium-priced grant of 729,927 options @ $10.44. In addition, 421,496 restricted stock units were granted on 1 Apr 2025. All awards vest ratably over three years.
The net effect is an incremental cash purchase signalling management confidence at a price well below option strikes, while the large option/RSU package further aligns incentives but introduces future dilution risk.